Drugs That Cause Myocarditis
The most important drug classes causing myocarditis are immune checkpoint inhibitors (ICIs), antipsychotics (especially clozapine), COVID-19 mRNA vaccines, mesalazine, and smallpox vaccines, with ICIs carrying the highest mortality risk at 32.5%. 1, 2
High-Risk Drug Categories
Immune Checkpoint Inhibitors (Highest Mortality)
ICIs represent the most lethal form of drug-induced myocarditis with a 32.5% mortality rate 2. The most frequently implicated agents include:
- Nivolumab (ROR 23.21) - most reported ICI 1
- Pembrolizumab (ROR 19.90) 1
- Atezolizumab (ROR 20.75) 1
- Cemiplimab (ROR 38.84) 1
- Ipilimumab 3
Key clinical features: Median onset is 5.7 weeks but ranges from 1-84 weeks 4. Half of confirmed cases present with normal left ventricular ejection fraction 5. Troponin elevation is nearly universal, and ECG abnormalities (especially ST-segment elevation) are common [@1-4@, @8-9@].
Critical management points: ICI therapy must be permanently discontinued in most cases of confirmed myocarditis [@6-7@, 5]. Initiate IV methylprednisolone 500-1000 mg daily for 3 days immediately 5. For steroid-refractory cases, consider antithymocyte globulin, infliximab (avoid in heart failure), mycophenolate mofetil, or abatacept [@6-7@].
Antipsychotics (Most Frequently Reported)
Clozapine is the single most reported drug associated with myocarditis (N=1,269 reports, ROR 35.21) 1. This class has been recognized since 1979 and remains the most frequently reported category 2.
- Clozapine - highest signal strength among antipsychotics
- Olanzapine (N=191 reports) 1
Mortality: Significantly lower than ICIs but still substantial 2.
Inflammatory Bowel Disease Medications
Mesalazine shows the strongest disproportionality signal (ROR 48.01) among all drugs 1:
Onset characteristics: Time to onset varies significantly among these drugs 6. Myocarditis can occur regardless of patient age or sex 6. Note that ulcerative colitis itself may independently induce myocarditis, creating diagnostic complexity 6.
Vaccines
- COVID-19 mRNA vaccines - rare but well-documented, highest rates in males aged 12-29 years after second dose [@1-4@, @8-9@, 3]
- Smallpox vaccine 3
- Influenza vaccine 3
Risk-benefit for COVID-19 vaccines: Per 1 million males aged 12-29 receiving second mRNA dose: 39-47 myocarditis cases versus prevention of 560 hospitalizations, 138 ICU admissions, and 6 deaths [@8-9@]. The benefit-to-risk ratio remains highly favorable [@1-4@, @8-9@].
Additional High-Risk Drugs
Diagnostic Approach
When drug-induced myocarditis is suspected, immediately obtain:
- ECG - look for ST-segment elevation (most common finding) [@1-4@, @8-9@]
- High-sensitivity cardiac troponin - elevated in vast majority, peaks ~3 days post-onset [@1-4@, @8-9@]
- Echocardiogram - 50% have normal LVEF at presentation; assess global longitudinal strain 5
- Cardiac MRI with inflammatory sequences (T2-STIR, T1, LGE) - recommended for hemodynamically stable patients [@1-4@, 5]
If CMR is non-diagnostic: Consider cardiac PET-CT with 18F-FDG or 68Ga-DOTATOC 5. Endomyocardial biopsy should be considered when diagnosis remains uncertain before restarting causative therapy 5.
Risk Stratification
Admit all suspected cases to level 2 or 3 care with continuous ECG monitoring and resuscitation capabilities 5. Patients with fulminant myocarditis (cardiogenic shock, sustained ventricular arrhythmias, advanced AV block) require advanced heart failure centers with mechanical circulatory support expertise [@1-4@].
Time Course
Median time to onset: 15 days (IQR: 10-23 days) across all drug classes 2. However, this varies significantly:
- ICIs: 5.7 weeks median (range 1-84 weeks) 4
- COVID-19 mRNA vaccines: 2-3 days after second dose [@1-4@, @8-9@]
Overall Mortality
Mortality rate is 10.3% overall but varies dramatically by drug class 2:
- Immunotherapies: 32.5% (highest)
- Salicylates: 2.6% (lowest)
- Most patients recover with appropriate treatment 6
Critical Pitfall
Do not assume normal LVEF excludes myocarditis - half of ICI-associated myocarditis cases present with preserved ejection fraction 5. Reduction in global longitudinal strain on echocardiography predicts worse outcomes 5.